Related Experiment Videos
Has chemotherapy anywhere to go?
1Toxicology Unit, Medical Research Council Laboratories, Carshalton, Surrey.
Abstract:
The methods used in the past to detect anticancer agents should be replaced by new approaches, where the aim is specifically to find treatments for the common solid cancers. Programmes have now been introduced which allow the rapid preclinical development and clinical trial of new classes of chemical. Provided sensitive markers of tumour response can be developed, new types of anticancer agent with activity against solid cancer should be discovered.
Insights
Traditional anticancer agent detection methods need updating to focus on solid cancer treatments. New programs enable faster development, and sensitive tumor response markers could lead to discovering novel solid cancer drugs.
Area of Science:
- Oncology
- Drug Discovery
- Cancer Therapeutics
Background:
- Current methods for detecting anticancer agents are insufficient for targeting common solid cancers.
- There is a need for novel therapeutic strategies against solid tumors.
Purpose of the Study:
- To advocate for the replacement of outdated detection methods with new approaches.
- To highlight the potential of new chemical classes in treating solid cancers.
- To emphasize the importance of developing sensitive markers for tumor response.
Main Methods:
- Introduction of new programs for rapid preclinical development of chemical agents.
- Focus on identifying and developing sensitive markers of tumor response.
Main Results:
- New programs facilitate swift preclinical and clinical evaluation of novel chemical agents.
- Development of sensitive markers is crucial for identifying effective treatments.
Conclusions:
- Advancement in anticancer agent discovery requires a shift towards solid cancer-specific approaches.
- Successful identification of novel anticancer agents hinges on developing robust tumor response markers.